Core Viewpoint - FibroBiologics, Inc. has announced a registered direct offering of 4,477,614 shares of common stock at $0.335 per share, along with a concurrent private placement of unregistered warrants for the same number of shares at the same exercise price, aiming to raise approximately $1.5 million in gross proceeds [1][3]. Group 1: Offering Details - The offering consists of 4,477,614 shares of common stock priced at $0.335 each, with a concurrent issuance of unregistered warrants to purchase the same number of shares at the same price [1]. - The closing of the offering is expected around November 25, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2]. Group 2: Financial Implications - The total gross proceeds from the offering are anticipated to be approximately $1.5 million before deducting fees and expenses [3]. - If the unregistered warrants are fully exercised, an additional gross proceeds of approximately $1.5 million could be realized [3]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes [3]. Group 3: Regulatory Information - The shares are being offered under a "shelf" registration statement on Form S-3, which became effective on February 10, 2025 [4]. - The unregistered warrants and shares from the private placement are offered under Section 4(a)(2) of the Securities Act and have not been registered [5]. Group 4: Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells, holding over 270 patents [9]. - The company is engaged in various clinical pathways, including wound healing, multiple sclerosis, and cancer, representing advancements in cell therapy and tissue regeneration [9].
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules